^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) + Mektovi (binimetinib) (MEK inhibitor) + Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)
Excerpt:
Histologically confirmed stage III (unresectable) or stage IV melanoma with the BRAF V600 mutation.
Trial ID:
Source:
Title:
LBA40 - SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study
Published date:
09/13/2021
Excerpt:
From Nov 2016 to May 2019, 37 sites in 9 countries enrolled 251 patients with untreated, metastatic BRAFV600-mutated melanoma. Patients were randomized to Arm A [E+B until PD, followed by I+N until PD], or Arm B (I+N until PD, followed by E+B until PD) or Arm C (E+B for 8 weeks, followed by I+N until PD, followed by E+B until PD)....The survival rate at 2 and 3 years was 65% and 54% in arm A, 73% and 62% in arm B and 69% and 60% in arm C respectively. Total PFS rate at 2 and 3 years was 46% and 41% in arm A, 65% and 53% in arm B, 57% and 54% in arm C....The OS and TPFS rates at 2 and 3 years showed a better trend in arm B and C.
Trial ID:
Source:
Title:
LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Published date:
09/19/2020
Excerpt:
...patients with untreated, metastatic BRAFV600 mutated melanoma, were enrolled at 37 centers in 9 countries....In the 3 Arms 1-year PFS was 60%, 43% and 46% and 2-year PFS was 35%, 38% and 39% respectively. ORR was 82.6% (CR 21.7%) in Arm A, 45.1% (CR 15.5%) in Arm B and 78.3% (CR 29.0%) in Arm C.
Trial ID:
